2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
14
Lung Neoplasms
11
Breast Neoplasms
9
Colorectal Neoplasms
8
Prostatic Neoplasms
7
Stomach Neoplasms
3
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Smoking Cessation
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic cancer, adult
2
Ovarian Neoplasms
2
Neoplastic Cells, Circulating
2
Motor Activity
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
2
Endometrial Neoplasms
2
Disease
2
Wilms Tumor
1
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Interventions
Temozolomide
405
Radiotherapy
202
Bevacizumab
157
Radiation
80
Magnetic Resonance Spectroscopy
77
Lomustine
49
Surgical Procedures, Operative
45
Carmustine
41
pembrolizumab
40
Irinotecan
38
Nivolumab
32
Specimen Handling
28
Carboplatin
27
Radiosurgery
24
Erlotinib Hydrochloride
24
Drug Therapy
23
Chemotherapy, Adjuvant
23
Radiotherapy, Intensity-Modulated
22
Cyclophosphamide
20
Aminolevulinic Acid
20
O(6)-benzylguanine
17
sargramostim
16
Radiotherapy, Conformal
15
Blood Specimen Collection
15
temsirolimus
14
Granulocyte-Macrophage Colony-Stimulating Factor
14
Everolimus
14
Vorinostat
13
Sorafenib
13
Ipilimumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Hematologic Tests
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled